Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Cabozantinib (XL184) in Combination With High-dose Ifosfamide in Adults and Children With Relapsed/Refractory Sarcomas (CaIRS Trial)

NCT06156410 is registered in ClinicalTrials.gov with Children's Hospital of Philadelphia as lead sponsor.

NCT NCT06156410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06156410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Cabozantinib (XL184) in Combination With High-dose Ifosfamide in Adults and Children With Relapsed/Refractory Sarcomas (CaIRS Trial)
Lead sponsor
Children's Hospital of Philadelphia
Phase
Phase 1
Overall status
Recruiting
Start date
October 24, 2023
Completion date
November 30, 2028
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, osteosarcoma, sarcomas